Published on 12/03/2012
NHS Scotland is due to make a decision on funding for prostate cancer drug Abiraterone, which has already been turned down for use on the NHS in England.
Prostate cancer drug Abiraterone has been shown to extend the life of sufferers for more than three months. Whilst it is a not a cure for the disease, it can give men some extra time with their families.
However, Abiraterone costs £3,000 a month and has been provisionally rejected for use in England and Wales.
Watchdog NICE decided that the drug did not justify the price tag in its provisional judgement. However, advisors in Wales have approved its use until NICE makes its final decision.
For patients in England, Abiraterone is only available through the government’s Cancer Drugs Fund or through their private medical insurance.
Now, the Scottish NHS is to decide whether it will fund the drug for prostate cancer sufferers.
With the NHS under financial pressure there are many licensed drugs which are too expensive to be funded for use on the NHS.
One way to ensure you get access to the best drugs available is to compare health insurance quotes. Private medical insurance will cover the cost of expensive treatment even if it is not approved by NICE.
© ActiveQuote Ltd. 2012Categories: Medical
, NHS and Hospitals